Elicio Therapeutics, Inc. Interest Expense Nonoperating
Elicio Therapeutics, Inc. (ELTX) reported Interest Expense Nonoperating of $410.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- Elicio Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $410.00K, a 111.34% increase year-over-year.
- Elicio Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $407.00K, a 131.25% increase year-over-year.
- Elicio Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $337.00K, a 44.02% increase year-over-year.
- Elicio Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $426.00K, a 210.95% increase year-over-year.
- Elicio Therapeutics, Inc. interest expense nonoperating for fiscal 2025 was $1.13M, a 149.01% increase from fiscal 2024.
- Elicio Therapeutics, Inc. interest expense nonoperating for fiscal 2024 was $455.00K, a 57.03% decline from fiscal 2023.
- Elicio Therapeutics, Inc. interest expense nonoperating for fiscal 2023 was $1.06M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $410.00K 10-Q · filed 2026-08-13 | $817.00K 10-Q · filed 2026-08-13 | $1.15M derived: sum of 3 quarters · filed 2026-08-13 | $1.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $407.00K 10-Q · filed 2026-05-11 | $744.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.17M derived: sum of 3 quarters · filed 2026-05-11 | $1.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $763.00K derived: sum of 2 quarters · filed 2026-03-12 | $957.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.13M 10-K · filed 2026-03-12 |
| 2025-09-30 | $426.00K 10-Q · filed 2025-11-13 | $620.00K derived: sum of 2 quarters · filed 2026-08-13 | $796.00K 10-Q · filed 2025-11-13 | $1.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $194.00K 10-Q · filed 2026-08-13 | $370.00K 10-Q · filed 2026-08-13 | $604.00K derived: sum of 3 quarters · filed 2026-08-13 | $741.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $176.00K 10-Q · filed 2026-05-11 | $410.00K derived: sum of 2 quarters · filed 2026-05-11 | $547.00K derived: sum of 3 quarters · filed 2026-05-11 | $596.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $371.00K derived: sum of 2 quarters · filed 2026-03-12 | $420.00K derived: sum of 3 quarters · filed 2026-03-12 | $455.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $137.00K 10-Q · filed 2025-11-13 | $186.00K derived: sum of 2 quarters · filed 2025-11-13 | $221.00K 10-Q · filed 2025-11-13 | $224.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $49.00K 10-Q · filed 2025-08-07 | $85.00K 10-Q · filed 2025-08-07 | $87.00K derived: sum of 3 quarters · filed 2025-08-07 | $88.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $36.00K 10-Q · filed 2025-05-13 | $38.00K derived: sum of 2 quarters · filed 2025-05-13 | $39.00K derived: sum of 3 quarters · filed 2025-05-13 | $753.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $3.00K derived: sum of 2 quarters · filed 2025-03-31 | $717.00K derived: sum of 3 quarters · filed 2025-03-31 | $1.06M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.00K 10-Q · filed 2024-11-13 | $715.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.06M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $714.00K 10-Q · filed 2024-08-13 | $1.06M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |